TG Therapeutics announced upcoming presentations of Briumvi (ublituximab-xiiy) data for relapsing multiple sclerosis (RMS) at the American Academy of Neurology 2025 annual meeting. The presentations will cover various aspects of Briumvi, including long-term safety, infusion tolerability, real-world efficacy, and a modified regimen. The data will be presented via posters between April 7th and 9th, 2025.
These presentations are important because they offer further insights into the long-term use and effectiveness of Briumvi in a real-world setting. Data on long-term immunoglobulin levels and serious infections will be crucial for physicians making treatment decisions. Additionally, the exploration of a modified Briumvi regimen could potentially improve treatment outcomes for RMS patients.
The presentations will feature data from various studies, including the ULTIMATE I & II Phase 3 trials’ open-label extension, a real-world observational survey (ENAMOR), the ENABLE Phase 4 observational study, and a study evaluating a modified Briumvi regimen (ENHANCE). The posters will delve into specific topics such as the association between decreased immunoglobulin levels and serious infections, infusion tolerability, and five-year outcomes with Briumvi.
This information is expected to further solidify Briumvi’s position as a treatment option for RMS. Positive results from the real-world studies and the modified regimen could expand Briumvi’s market reach and benefit a wider range of patients. The forthcoming data will be crucial for ongoing assessment of Briumvi’s long-term safety and efficacy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
